{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T09:15:08Z","timestamp":1775639708804,"version":"3.50.1"},"reference-count":34,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,15]],"date-time":"2022-12-15T00:00:00Z","timestamp":1671062400000},"content-version":"am","delay-in-days":379,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bulletin du Cancer"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1016\/j.bulcan.2020.11.015","type":"journal-article","created":{"date-parts":[[2021,3,4]],"date-time":"2021-03-04T15:18:07Z","timestamp":1614871087000},"page":"S65-S71","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"S","title":["Suivi au moyen-terme des patients faisant l\u2019objet d\u2019un traitement par CAR-T cells\u00a0: recommandations de la Soci\u00e9t\u00e9 francophone de greffe de moelle et de th\u00e9rapie cellulaire (SFGM-TC)"],"prefix":"10.1016","volume":"108","author":[{"given":"Tamim","family":"Alsuliman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurianne","family":"Drieu La Rochelle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arnaud","family":"Campidelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R\u00e9my","family":"Dul\u00e9ry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amandine","family":"Fayard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne-Claire","family":"Mamez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Baptiste","family":"Mear","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pascale Odinet","family":"Schneider","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aur\u00e9lie","family":"Trevet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C\u00e9line","family":"Vicente","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ibrahim","family":"Yakoub-Agha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.bulcan.2020.11.015_bib0175","first-page":"17","article-title":"Treatment with anti CD19\u00a0chimeric antigen receptor T cells after antibody-based immunotherapy in adults with acute lymphoblastic leukemia","volume":"68","author":"Danylesko","year":"2019","journal-title":"Curr Res Transl Med"},{"key":"10.1016\/j.bulcan.2020.11.015_bib0180","first-page":"93","article-title":"Chimeric antigen-receptor T-cell therapy for hematological malignancies and solid tumors: Clinical data to date, current limitations and perspectives","volume":"65","author":"Gauthier","year":"2017","journal-title":"Curr Res Transl Med"},{"issue":"2","key":"10.1016\/j.bulcan.2020.11.015_bib0185","first-page":"43","article-title":"Chimeric antigen receptor T cell therapy for non-Hodgkin lymphoma","volume":"66","author":"Ghobadi","year":"2018","journal-title":"Curr Res Transl Med"},{"issue":"2","key":"10.1016\/j.bulcan.2020.11.015_bib0190","first-page":"62","article-title":"Beginning the CAR T cell therapy revolution in the US and EU","volume":"66","author":"Grupp","year":"2018","journal-title":"Curr Res Transl Med"},{"issue":"2","key":"10.1016\/j.bulcan.2020.11.015_bib0195","first-page":"35","article-title":"CAR T-cells: A John von Neumann legacy?","volume":"66","author":"Quesnel","year":"2018","journal-title":"Curr Res Transl Med"},{"issue":"4","key":"10.1016\/j.bulcan.2020.11.015_bib0200","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1158\/2159-8290.CD-12-0548","article-title":"The basic principles of chimeric antigen receptor design","volume":"3","author":"Sadelain","year":"2013","journal-title":"Cancer Discov"},{"issue":"5","key":"10.1016\/j.bulcan.2020.11.015_bib0205","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1111\/bjh.13889","article-title":"Chimeric Antigen Receptor (CAR) therapy for multiple myeloma","volume":"172","author":"Atanackovic","year":"2016","journal-title":"Br J Haematol"},{"issue":"5","key":"10.1016\/j.bulcan.2020.11.015_bib0210","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1097\/CCO.0000000000000667","article-title":"Clinical data, limitations and perspectives on chimeric antigen receptor T-cell therapy in multiple myeloma","volume":"32","author":"Beauvais","year":"2020","journal-title":"Curr Opin Oncol"},{"issue":"0","key":"10.1016\/j.bulcan.2020.11.015_bib0215","article-title":"Retargeting of T lymphocytes to PSCA- or PSMA positive prostate cancer cells using the novel modular chimeric antigen receptor platform technology \u201cUniCAR\u201d","volume":"5","author":"Feldmann","year":"2014","journal-title":"Oncotarget"},{"issue":"2","key":"10.1016\/j.bulcan.2020.11.015_bib0220","first-page":"50","article-title":"Insights into cytokine release syndrome and neurotoxicity after CD19-specific CAR-T cell therapy","volume":"66","author":"Gauthier","year":"2018","journal-title":"Curr Res Transl Med"},{"issue":"3","key":"10.1016\/j.bulcan.2020.11.015_bib0225","doi-asserted-by":"crossref","first-page":"e76","DOI":"10.1016\/j.bbmt.2018.12.068","article-title":"Clinical Utilization of Chimeric Antigen Receptor T Cells in B Cell Acute Lymphoblastic Leukemia: An Expert Opinion from the European Society for Blood and Marrow Transplantation and the American Society for Blood and Marrow Transplantation","volume":"25","author":"Kansagra","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"11S","key":"10.1016\/j.bulcan.2020.11.015_bib0230","doi-asserted-by":"crossref","first-page":"S193","DOI":"10.1016\/j.bulcan.2016.09.006","article-title":"[How we harmonize HSCT clinical practices among the SFGM-TC centers]","volume":"103","author":"Tipton","year":"2016","journal-title":"Bull Cancer"},{"key":"10.1016\/j.bulcan.2020.11.015_bib0235","first-page":"79","article-title":"An international survey on the management of patients receiving CAR T-cell therapy for haematological malignancies on behalf of the Chronic Malignancies Working Party of EBMT","volume":"67","author":"Hayden","year":"2019","journal-title":"Curr Res Transl Med"},{"issue":"16","key":"10.1016\/j.bulcan.2020.11.015_bib0240","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","article-title":"Chimeric antigen receptor T cells for sustained remissions in leukemia","volume":"371","author":"Maude","year":"2014","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.bulcan.2020.11.015_bib0245","doi-asserted-by":"crossref","first-page":"297","DOI":"10.3324\/haematol.2019.229781","article-title":"Management of adults and children undergoing chimeric antigen receptor T-cell therapy: best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE)","volume":"105","author":"Yakoub-Agha","year":"2020","journal-title":"Haematologica"},{"issue":"1S","key":"10.1016\/j.bulcan.2020.11.015_bib0250","doi-asserted-by":"crossref","first-page":"S102","DOI":"10.1016\/j.bulcan.2018.12.001","article-title":"[Management of cytokine release syndrome in adult and pediatric patients undergoing CAR-T cell therapy for hematological malignancies: Recommendation of the French Society of Bone Marrow and cellular Therapy (SFGM-TC)]","volume":"106","author":"Yakoub-Agha","year":"2019","journal-title":"Bull Cancer"},{"issue":"1","key":"10.1016\/j.bulcan.2020.11.015_bib0255","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.bbmt.2019.09.037","article-title":"Patient-Reported Neuropsychiatric Outcomes of Long-Term Survivors after Chimeric Antigen Receptor T Cell Therapy","volume":"26","author":"Ruark","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"10","key":"10.1016\/j.bulcan.2020.11.015_bib0260","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1038\/s41409-019-0487-3","article-title":"Early and late hematologic toxicity following CD19\u00a0CAR-T cells","volume":"54","author":"Fried","year":"2019","journal-title":"Bone Marrow Transplant"},{"issue":"5","key":"10.1016\/j.bulcan.2020.11.015_bib0265","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.bulcan.2020.11.015_bib0270","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.bbmt.2019.08.003","article-title":"Late Events after Treatment with CD19-Targeted Chimeric Antigen Receptor Modified T Cells","volume":"26","author":"Cordeiro","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bulcan.2020.11.015_bib0275","doi-asserted-by":"crossref","first-page":"100596","DOI":"10.1016\/j.blre.2019.100596","article-title":"CAR-T - and a side order of IgG, to go? - Immunoglobulin replacement in patients receiving CAR-T cell therapy","volume":"38","author":"Hill","year":"2019","journal-title":"Blood Rev"},{"issue":"3","key":"10.1016\/j.bulcan.2020.11.015_bib0280","doi-asserted-by":"crossref","first-page":"e28092","DOI":"10.1002\/pbc.28092","article-title":"Subcutaneous immunoglobulin replacement following CD19-specific chimeric antigen receptor T-cell therapy for B-cell acute lymphoblastic leukemia in pediatric patients","volume":"67","author":"Arnold","year":"2019","journal-title":"Pediatr Blood Cancer"},{"issue":"2","key":"10.1016\/j.bulcan.2020.11.015_bib0285","doi-asserted-by":"crossref","first-page":"123","DOI":"10.2217\/imt-2016-0127","article-title":"Donor origin CAR T cells: graft versus malignancy effect without GVHD, a systematic review","volume":"9","author":"Anwer","year":"2017","journal-title":"Immunotherapy"},{"issue":"3","key":"10.1016\/j.bulcan.2020.11.015_bib0290","first-page":"79","article-title":"An international survey on the management of patients receiving CAR T-cell therapy for haematological malignancies on beeehalf of the Chronic Malignancies Working Party of EBMT","volume":"67","author":"Hayden","year":"2019","journal-title":"Curr Res Transl Med"},{"issue":"1","key":"10.1016\/j.bulcan.2020.11.015_bib0295","first-page":"17","article-title":"Treatment with anti CD19\u00a0chimeric antigen receptor T cells after antibody-based immunotherapy in adults with acute lymphoblastic leukemia","volume":"68","author":"Danylesko","year":"2020","journal-title":"Curr Res Transl Med"},{"issue":"4","key":"10.1016\/j.bulcan.2020.11.015_bib0300","first-page":"159","article-title":"Real world experience of approved chimeric antigen receptor T-cell therapies outside of clinical trials","volume":"68","author":"Yassine","year":"2020","journal-title":"Curr Res Transl Med"},{"issue":"1","key":"10.1016\/j.bulcan.2020.11.015_bib0305","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1182\/blood-2017-07-793760","article-title":"Infectious complications of CD19-targeted chimeric antigen receptor-modified T-cell immunotherapy","volume":"131","author":"Hill","year":"2018","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.bulcan.2020.11.015_bib0310","first-page":"111","article-title":"CAR T-cell treatment during the COVID-19\u00a0pandemic: Management strategies and challenges","volume":"68","author":"Hu","year":"2020","journal-title":"Curr Res Transl Med"},{"issue":"1","key":"10.1016\/j.bulcan.2020.11.015_bib0315","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","article-title":"Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2\u00a0trial","volume":"20","author":"Locke","year":"2019","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.bulcan.2020.11.015_bib0320","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N Engl J Med"},{"issue":"26","key":"10.1016\/j.bulcan.2020.11.015_bib0325","doi-asserted-by":"crossref","first-page":"4017","DOI":"10.1182\/blood-2014-12-580068","article-title":"CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia","volume":"125","author":"Maude","year":"2015","journal-title":"Blood"},{"issue":"26","key":"10.1016\/j.bulcan.2020.11.015_bib0330","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.bulcan.2020.11.015_bib0335","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1182\/blood-2017-07-793760","article-title":"Infectious complications of CD19-targeted chimeric antigen receptor-modified T-cell immunotherapy","volume":"131","author":"Hill","year":"2017","journal-title":"Blood"},{"issue":"26","key":"10.1016\/j.bulcan.2020.11.015_bib0170","doi-asserted-by":"crossref","first-page":"2800","DOI":"10.1182\/blood.2019000888","article-title":"Safety of CAR Tcell therapy in patients with B-cell lymphoma and chronic hepatitis B or C virus infection","volume":"133","author":"Strati","year":"2019","journal-title":"Blood"}],"container-title":["Bulletin du Cancer"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455121000412?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455121000412?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T19:34:39Z","timestamp":1757792079000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0007455121000412"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":34,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["S0007455121000412"],"URL":"https:\/\/doi.org\/10.1016\/j.bulcan.2020.11.015","relation":{},"ISSN":["0007-4551"],"issn-type":[{"value":"0007-4551","type":"print"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Suivi au moyen-terme des patients faisant l\u2019objet d\u2019un traitement par CAR-T cells\u00a0: recommandations de la Soci\u00e9t\u00e9 francophone de greffe de moelle et de th\u00e9rapie cellulaire (SFGM-TC)","name":"articletitle","label":"Article Title"},{"value":"Bulletin du Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bulcan.2020.11.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Soci\u00e9t\u00e9 Fran\u00e7aise du Cancer. Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}